查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1442840

轉移性骨病市場（治療：藥物、放射治療、手術介入和腫瘤消融治療）- 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢和預測

Metastatic Bone Disease Market (Treatment: Medication, Radiation Therapy, Surgical Intervention, and Tumor Ablation Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 202 Pages | 商品交期: 2-10個工作天內

價格

轉移性骨病市場 - 報告範圍

TMR 關於全球轉移性骨疾病市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球轉移性骨疾病的收入2017- 2031年期間的市場，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球轉移性骨病市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解轉移性骨疾病市場。

該報告深入探討了全球轉移性骨病市場的競爭格局。全球轉移性骨疾病市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球轉移性骨疾病市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：按處理方式

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依處理方式，2017-2031
    • 藥物
      • 化療
      • 荷爾蒙療法
      • 雙磷酸鹽
      • 鴉片類藥物治療
      • 免疫療法
    • 放射治療
    • 手術治療
    • 腫瘤消融治療
  • 市場吸引力：按待遇

第 7 章：全球市場分析與預測：依轉移來源分類

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依轉移來源分類，2017-2031
    • 胸部
    • 肺
    • 甲狀腺
    • 腎
    • 攝護腺
    • 其他
  • 市場吸引力：依轉移來源分類

第 8 章：全球市場分析與預測：按提供者類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依提供者類型，2017-2031
    • OEM
    • 非OEM
  • 市場吸引力：按提供者類型分類

第 9 章：全球市場分析與預測：按最終用戶

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2017-2031
    • 醫院
    • 專科診所
    • 門診手術中心
  • 市場吸引力：按最終用戶分類

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 11 章：北美市場分析與預測

第 12 章：歐洲市場分析與預測

第 13 章：亞太市場分析與預測

第 14 章：拉丁美洲市場分析與預測

第 15 章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Amgen, Inc.
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Eli Lilly and Company
    • Bayer AG
    • Fresenius Kabi AG
    • Boston Scientific Corporation
    • Medtronic
Product Code: TMRGL37802

Metastatic Bone Disease Market - Scope of Report

TMR's report on the global metastatic bone disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global metastatic bone disease market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global metastatic bone disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the metastatic bone disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global metastatic bone disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global metastatic bone disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global metastatic bone disease market.

The report delves into the competitive landscape of the global metastatic bone disease market. Key players operating in the global metastatic bone disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global metastatic bone disease market profiled in this report.

Key Questions Answered in Global metastatic bone disease Market Report:

  • What is the sales/revenue generated by metastatic bone disease across all regions during the forecast period?
  • What are the opportunities in the global metastatic bone disease market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Metastatic Bone Disease Market - Research Objectives and Research Approach

The comprehensive report on the global metastatic bone disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global metastatic bone disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global metastatic bone disease market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Metastatic Bone Disease Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Metastatic Bone Disease Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Metastatic Bone Disease Market Analysis and Forecast, by Treatment

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment, 2017-2031
    • 6.3.1. Medication
      • 6.3.1.1. Chemotherapy
      • 6.3.1.2. Hormone Therapy
      • 6.3.1.3. Bisphosphonates
      • 6.3.1.4. Opiate Therapy
      • 6.3.1.5. Immunotherapy
    • 6.3.2. Radiation Therapy
    • 6.3.3. Surgical Intervention
    • 6.3.4. Tumor Ablation Therapy
  • 6.4. Market Attractiveness, by Treatment

7. Global Metastatic Bone Disease Market Analysis and Forecast, by Origin of Metastasis

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Origin of Metastasis, 2017-2031
    • 7.3.1. Breast
    • 7.3.2. Lung
    • 7.3.3. Thyroid
    • 7.3.4. Kidney
    • 7.3.5. Prostate
    • 7.3.6. Others
  • 7.4. Market Attractiveness, by Origin of Metastasis

8. Global Metastatic Bone Disease Market Analysis and Forecast, by Provider Type

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Provider Type, 2017-2031
    • 8.3.1. OEM
    • 8.3.2. Non-OEM
  • 8.4. Market Attractiveness, by Provider Type

9. Global Metastatic Bone Disease Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Ambulatory Surgical Centers
  • 9.4. Market Attractiveness, by End-user

10. Global Metastatic Bone Disease Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Metastatic Bone Disease Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment, 2017-2031
    • 11.2.1. Medication
      • 11.2.1.1. Chemotherapy
      • 11.2.1.2. Hormone Therapy
      • 11.2.1.3. Bisphosphonates
      • 11.2.1.4. Opiate Therapy
      • 11.2.1.5. Immunotherapy
    • 11.2.2. Radiation Therapy
    • 11.2.3. Surgical Intervention
    • 11.2.4. Tumor Ablation Therapy
  • 11.3. Market Attractiveness, by Treatment
  • 11.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
    • 11.4.1. Breast
    • 11.4.2. Lung
    • 11.4.3. Thyroid
    • 11.4.4. Kidney
    • 11.4.5. Prostate
    • 11.4.6. Others
  • 11.5. Market Attractiveness, by Origin of Metastasis
  • 11.6. Market Value Forecast, by Provider Type, 2017-2031
    • 11.6.1. OEM
    • 11.6.2. Non-OEM
  • 11.7. Market Attractiveness, by Provider Type
  • 11.8. Market Value Forecast, by End-user
    • 11.8.1. Hospitals
    • 11.8.2. Specialty Clinics
    • 11.8.3. Ambulatory Surgical Centers
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Treatment
    • 11.11.2. By Origin of Metastasis
    • 11.11.3. By Provider Type
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Metastatic Bone Disease Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment, 2017-2031
    • 12.2.1. Medication
      • 12.2.1.1. Chemotherapy
      • 12.2.1.2. Hormone Therapy
      • 12.2.1.3. Bisphosphonates
      • 12.2.1.4. Opiate Therapy
      • 12.2.1.5. Immunotherapy
    • 12.2.2. Radiation Therapy
    • 12.2.3. Surgical Intervention
    • 12.2.4. Tumor Ablation Therapy
  • 12.3. Market Attractiveness, by Treatment
  • 12.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
    • 12.4.1. Breast
    • 12.4.2. Lung
    • 12.4.3. Thyroid
    • 12.4.4. Kidney
    • 12.4.5. Prostate
    • 12.4.6. Others
  • 12.5. Market Attractiveness, by Origin of Metastasis
  • 12.6. Market Value Forecast, by Provider Type, 2017-2031
    • 12.6.1. OEM
    • 12.6.2. Non-OEM
  • 12.7. Market Attractiveness, by Provider Type
  • 12.8. Market Value Forecast, by End-user, 2017-2031
    • 12.8.1. Hospitals
    • 12.8.2. Specialty Clinics
    • 12.8.3. Ambulatory Surgical Centers
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Treatment
    • 12.11.2. By Origin of Metastasis
    • 12.11.3. By Provider Type
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Metastatic Bone Disease Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment, 2017-2031
    • 13.2.1. Medication
      • 13.2.1.1. Chemotherapy
      • 13.2.1.2. Hormone Therapy
      • 13.2.1.3. Bisphosphonates
      • 13.2.1.4. Opiate Therapy
      • 13.2.1.5. Immunotherapy
    • 13.2.2. Radiation Therapy
    • 13.2.3. Surgical Intervention
    • 13.2.4. Tumor Ablation Therapy
  • 13.3. Market Attractiveness, by Treatment
  • 13.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
    • 13.4.1. Breast
    • 13.4.2. Lung
    • 13.4.3. Thyroid
    • 13.4.4. Kidney
    • 13.4.5. Prostate
    • 13.4.6. Others
  • 13.5. Market Attractiveness, by Origin of Metastasis
  • 13.6. Market Value Forecast, by Provider Type, 2017-2031
    • 13.6.1. OEM
    • 13.6.2. Non-OEM
  • 13.7. Market Attractiveness, by Provider Type
  • 13.8. Market Value Forecast, by End-user, 2017-2031
    • 13.8.1. Hospitals
    • 13.8.2. Specialty Clinics
    • 13.8.3. Ambulatory Surgical Centers
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Treatment
    • 13.11.2. By Origin of Metastasis
    • 13.11.3. By Provider Type
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Metastatic Bone Disease Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Treatment, 2017-2031
    • 14.2.1. Medication
      • 14.2.1.1. Chemotherapy
      • 14.2.1.2. Hormone Therapy
      • 14.2.1.3. Bisphosphonates
      • 14.2.1.4. Opiate Therapy
      • 14.2.1.5. Immunotherapy
    • 14.2.2. Radiation Therapy
    • 14.2.3. Surgical Intervention
    • 14.2.4. Tumor Ablation Therapy
  • 14.3. Market Attractiveness, by Treatment
  • 14.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
    • 14.4.1. Breast
    • 14.4.2. Lung
    • 14.4.3. Thyroid
    • 14.4.4. Kidney
    • 14.4.5. Prostate
    • 14.4.6. Others
  • 14.5. Market Attractiveness, by Origin of Metastasis
  • 14.6. Market Value Forecast, by Provider Type, 2017-2031
    • 14.6.1. OEM
    • 14.6.2. Non-OEM
  • 14.7. Market Attractiveness, by Provider Type
  • 14.8. Market Value Forecast, by End-user, 2017-2031
    • 14.8.1. Hospitals
    • 14.8.2. Specialty Clinics
    • 14.8.3. Ambulatory Surgical Centers
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Treatment
    • 14.11.2. By Origin of Metastasis
    • 14.11.3. By Provider Type
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Metastatic Bone Disease Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Treatment, 2017-2031
    • 15.2.1. Medication
      • 15.2.1.1. Chemotherapy
      • 15.2.1.2. Hormone Therapy
      • 15.2.1.3. Bisphosphonates
      • 15.2.1.4. Opiate Therapy
      • 15.2.1.5. Immunotherapy
    • 15.2.2. Radiation Therapy
    • 15.2.3. Surgical Intervention
    • 15.2.4. Tumor Ablation Therapy
  • 15.3. Market Attractiveness, by Treatment
  • 15.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
    • 15.4.1. Breast
    • 15.4.2. Lung
    • 15.4.3. Thyroid
    • 15.4.4. Kidney
    • 15.4.5. Prostate
    • 15.4.6. Others
  • 15.5. Market Attractiveness, by Origin of Metastasis
  • 15.6. Market Value Forecast, by Provider Type, 2017-2031
    • 15.6.1. OEM
    • 15.6.2. Non-OEM
  • 15.7. Market Attractiveness, by Provider Type
  • 15.8. Market Value Forecast, by End-user, 2017-2031
    • 15.8.1. Hospitals
    • 15.8.2. Specialty Clinics
    • 15.8.3. Ambulatory Surgical Centers
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Treatment
    • 15.11.2. By Origin of Metastasis
    • 15.11.3. By Provider Type
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Amgen, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Merck & Co., Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. F. Hoffmann-La Roche Ltd.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Novartis AG
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Eli Lilly and Company
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Bayer AG
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Fresenius Kabi AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Boston Scientific Corporation
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Medtronic
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 02: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
  • Table 03: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
  • Table 04: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 08: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
  • Table 09: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
  • Table 10: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 11: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 13: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
  • Table 14: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
  • Table 15: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 16: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 18: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
  • Table 19: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
  • Table 20: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 23: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
  • Table 24: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
  • Table 25: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 28: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
  • Table 29: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
  • Table 30: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Metastatic Bone Disease Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Treatment, 2022
  • Figure 03: Global Metastatic Bone Disease Market Value Share, by Treatment, 2022
  • Figure 04: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Origin of Metastasis, 2022
  • Figure 05: Global Metastatic Bone Disease Market Value Share, by Origin of Metastasis, 2022
  • Figure 06: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Provider Type, 2022
  • Figure 07: Global Metastatic Bone Disease Market Value Share, by Provider Type, 2022
  • Figure 08: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
  • Figure 09: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
  • Figure 10: Global Metastatic Bone Disease Market Value Share, by Region, 2022
  • Figure 11: Global Metastatic Bone Disease Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 12: Global Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
  • Figure 13: Global Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
  • Figure 14: Global Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
  • Figure 15: Global Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
  • Figure 16: Global Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
  • Figure 17: Global Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
  • Figure 18: Global Metastatic Bone Disease Market Revenue (US$ Mn), by End-user, 2022
  • Figure 19: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
  • Figure 20: Global Metastatic Bone Disease Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 21: Global Metastatic Bone Disease Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 22: North America Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 23: North America Metastatic Bone Disease Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 24: North America Metastatic Bone Disease Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 25: North America Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
  • Figure 26: North America Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
  • Figure 27: North America Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
  • Figure 28: North America Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 29: North America Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
  • Figure 30: North America Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
  • Figure 31: North America Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
  • Figure 32: North America Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 33: Europe Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 34: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 35: Europe Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 36: Europe Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
  • Figure 37: Europe Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
  • Figure 38: Europe Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
  • Figure 39: Europe Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 40: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
  • Figure 41: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
  • Figure 42: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
  • Figure 43: Europe Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 44: Asia Pacific Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 45: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 46: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 47: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
  • Figure 48: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
  • Figure 49: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
  • Figure 50: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 51: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2017-2031
  • Figure 52: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
  • Figure 53: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
  • Figure 54: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 55: Latin America Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 56: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 57: Latin America Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 58: Latin America Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
  • Figure 59: Latin America Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
  • Figure 60: Latin America Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
  • Figure 61: Latin America Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 62: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
  • Figure 63: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
  • Figure 64: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
  • Figure 65: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 66: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 67: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 68: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 69: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
  • Figure 70: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
  • Figure 71: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
  • Figure 72: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 73: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
  • Figure 74: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
  • Figure 75: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
  • Figure 76: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031